Get the Stockscreener App
5.22
1.51%
-0.08
Annexon Inc stock is traded at $5.22, with a volume of 2.73M.
It is down -1.51% in the last 24 hours and down -1.51% over the past month.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
See More
Previous Close:
$5.30
Open:
$5.43
24h Volume:
2.73M
Relative Volume:
0.81
Market Cap:
$855.26M
Revenue:
-
Net Income/Loss:
$-196.48M
P/E Ratio:
-4.2935
EPS:
-1.2158
Net Cash Flow:
$-183.16M
1W Performance:
-10.00%
1M Performance:
-1.51%
6M Performance:
-23.01%
1Y Performance:
+104.71%
1-Day Range:
$5.155
$5.61
1-Week Range:
$4.96
$5.92
52-Week Range:
$2.03
$7.18
Annexon Inc Stock (ANNX) Company Profile
Name
Annexon Inc
Sector
Industry
Phone
(650) 822-5500
Address
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
5.22 | 855.26M | 0 | -196.48M | -183.16M | -1.2158 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-23 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-30-23 | Initiated | Wells Fargo | Overweight |
| May-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| May-25-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-16-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | BTIG Research | Buy |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Sep-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-26-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
View All
Annexon Inc Stock (ANNX) Latest News
Breakthrough research in geographic atrophy advanced by Annexon at ASRS2026 - Traders Union
Annexon Price Target Announced at $3.00/Share by Citizens - Moomoo
ANNX Initiates Coverage On by Citizens -- Rating Set to Market U - GuruFocus
Citizens initiates Annexon stock with underperform on GA trial concerns By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $14 - Moomoo
H.C. Wainwright reiterates Buy on Annexon stock, $14 target By Investing.com - Investing.com Canada
Weekly Recap: ARCHER II enrollment completed and 335K options to two hires - TradingView
How Investors Are Reacting To Annexon (ANNX) Phase 3 Tanruprubart Win And Vonaprument Updates - Yahoo Finance
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Two New Annexon Employees Receive 10-Year Options at $6.50 - Stock Titan
High Growth Tech Stocks To Watch In The US July 2026 - simplywall.st
Annexon grants new hires options for 335,000 shares at USD 6.5 each - Bitget
symbol__ Stock Quote Price and Forecast - CNN
Annexon (ANNX) filer Thomas Wiggans eyes 2,000-share NASDAQ stock sale - Stock Titan
Needham raises Annexon Biosciences stock price target to $25 on trial - Investing.com UK
Needham raises Annexon Biosciences stock price target to $25 on trial By Investing.com - Investing.com South Africa
Needham Maintains Annexon(ANNX.US) With Buy Rating, Raises Target Price to $25 - Moomoo
ANNX Maintained by Needham -- Price Target Raised to $25 - GuruFocus
FMR LLC's Strategic Acquisition of Annexon Inc Shares: A Detailed Analysis - GuruFocus
Annexon (ANNX) Presents Key Findings on Vision Preservation at A - GuruFocus
Annexon to present data on vonaprument for macular degeneration - Investing.com
Annexon to present data on vonaprument for macular degeneration By Investing.com - Investing.com Canada
Annexon to present Phase 2 ARCHER trial vision loss data for vonaprument at ASRS 2026 - Pluang
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026 - GlobeNewswire
Form 144 Annexon For: 14 July By Investing.com - Investing.com Nigeria
Annexon, Inc. SEC Filing (Jul 14, 2026) - Stock Titan
Annexon's tanruprubart shows strong Phase 3 res... - Pluang
Annexon: Perfect Complement To A Speculative Biotech Portfolio (NASDAQ:ANNX) - Seeking Alpha
Cantor Fitzgerald reiterates Overweight on Annexon stock By Investing.com - Investing.com Canada
Price to sales forward of Annexon, Inc. – NASDAQ:ANNX - TradingView
Price to book forward of Annexon, Inc. – NASDAQ:ANNX - TradingView
Enterprise value to revenue forward of Annexon, Inc. – NASDAQ:ANNX - TradingView
Enterprise value to EBITDA forward of Annexon, Inc. – BOATS:ANNX - TradingView
Price to earnings forward of Annexon, Inc. – NASDAQ:ANNX - TradingView
Annexon Inc. (ANNX) Slides 2.36% as Biotech Sector Faces HeadwindsPut Wall - dars.gov.et
Redmile Group (ANNX) reports 9.9% stake; RedCo II Offshore at 5.5% - Stock Titan
FMR LLC reports 11.9% stake in Annexon (NASDAQ: ANNX) - Stock Titan
Does Annexon’s Shift Into Russell Growth Indices Recast Its Core Equity Story for Investors (ANNX)? - simplywall.st
Annexon unveils eight research posters on Guillain-Barré syndrome and tanruprubart at EAN2026 - Traders Union
ANNXAnnexon Inc Options - Finviz
Annexon Inc. (ANNX) Q1 2026 Earnings: EPS Beat Drives Shares Higher Amid Pre-Revenue Pipeline ProgressGross Profit Margin - dars.gov.et
ANNX Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline, but Stock SlipsGuidance Downgrade Alert - dars.gov.et
Needham Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Annexon, Inc.(NasdaqGS: ANNX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Annexon, Inc.(NasdaqGS: ANNX) added to Russell 2500 Growth Benchmark - marketscreener.com
Annexon, Inc.(NasdaqGS: ANNX) dropped from Russell 2000 Value Benchmark - marketscreener.com
Annexon, Inc.(NasdaqGS: ANNX) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Annexon, Inc.(NasdaqGS: ANNX) added to Russell 2000 Growth Benchmark - marketscreener.com
Annexon, Inc.(NasdaqGS: ANNX) added to Russell 3000E Growth Benchmark - marketscreener.com
Annexon, Inc.(NasdaqGS: ANNX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Annexon, Inc.(NasdaqGS: ANNX) dropped from Russell 3000E Value Benchmark - marketscreener.com
Annexon Inc Stock (ANNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):